Review
Open access
Oct 2026
Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented substantial new data on antibody–drug conjugates (ADCs) in lung cancer, highlighting the ongoing expansion of ADC-based strategies from later-line treatment toward first-line combination regimens. This focused narrative review summarizes and...
Xiao-Lei Wang, Jia-Yuan Miao, Yuxuan Bao et al.
· Frontiers in Oncology · 0 citations